Compounds > forodesine
Page last updated: 2024-08-04 03:45:57

forodesine

Description

forodesine: structure in first source [MeSH]

immucillin H : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID135409409
CHEMBL ID218291
SCHEMBL ID16321929
SCHEMBL ID506383
CHEBI ID43362
MeSH IDM0292232

Synonyms (67)

Synonym
209799-67-7
immucillin-h
D06596
forodesine (usan/inn)
fodosine (tn)
IMH ,
1,4-dideoxy-4-aza-1-(s)-(9-deazahypoxanthin-9-yl)-d-ribitol
bcx-1777
fodosine
1NW4
2FF2
2FF1
1B8O
1G2O
nsc-717904
immucillin h
(1s)-1,4-dideoxy-4-imino-(9-deazahypoxanthin-9-yl)-d-ribitol
CHEBI:43362 ,
forodesine
7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
7-((2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl)-3h-pyrrolo[3,2-d]pyrimidin-4(5h)-one
bdbm50195587
7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
CHEMBL218291 ,
1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-iminoribitol
bcx 1777
nsc 717904
forodesine [usan:inn]
immh cpd
426x066elk ,
(-)-7-((2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl)-1,5-dihydro-4h-pyrrolo(3,2-d)pyrimidin-4-one
bcx1777
unii-426x066elk
4h-pyrrolo(3,2-d)pyrimidin-4-one, 7-((2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl)-1,5-dihydro-
forodesine [inn]
(-)-7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
forodesine [usan]
mundesine
forodesine [mi]
forodesine [who-dd]
IWKXDMQDITUYRK-KUBHLMPHSA-N
CS-3781
SCHEMBL16321929
SCHEMBL506383
7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydropyrrolo[2,3-e]pyrimidin-4-one
gtpl8272
fodosine (proposed trade name)
HY-16210
5(s),12(s)-dihete
(2r,3r,4s,5s)-2-(hydroxymethyl)-5-(4-hydroxy-5h-pyrrolo[3,2-d]pyrimidin-7-yl)pyrrolidine-3,4-diol
AKOS027326672
mfcd09837827
NCGC00485883-01
forodesine; immucillin h
7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-hydroxymethyl-2-pyrrolidinyl]-1,5-dihydro-4h-pyrrolo-[3,2-d]-pyrimidin-4-one
Q410040
TXFGPFIDYBMMJY-KUBHLMPHSA-N
(1s)-1,4-dideoxy-1-c-(4-hydroxypyrrolo[3,2-d]pyrimidin-7-yl)-1,4-imino-d-ribitol
DB06185
AS-35282
DTXSID50943276
7-((2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl)-3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
4h-pyrrolo[3,2-d]pyrimidin-4-one, 7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-3,5-dihydro-
AKOS040741759
EX-A7842M

Drug Classes (2)

ClassDescription
pyrrolopyrimidine
dihydroxypyrrolidine

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, PURINE NUCLEOSIDE PHOSPHORYLASEBos taurus (cattle)Ki0.0000AID977610
Chain A, PURINE NUCLEOSIDE PHOSPHORYLASEMycobacterium tuberculosisKi0.0000AID977610
Chain B, PURINE NUCLEOSIDE PHOSPHORYLASEMycobacterium tuberculosisKi0.0000AID977610
Chain A, IAG-nucleoside hydrolaseTrypanosoma vivaxKi0.0062AID977610
Chain A, IAG-nucleoside hydrolaseTrypanosoma vivaxKi0.0062AID977610
Purine nucleoside phosphorylaseHomo sapiens (human)IC500.0518AID272823; AID424677
Purine nucleoside phosphorylaseHomo sapiens (human)Ki0.0083AID1571176; AID1578784; AID164744; AID164928; AID164930; AID164938; AID272823; AID371442; AID409913; AID409914; AID410191
Purine nucleoside phosphorylaseMus musculus (house mouse)Ki0.0000AID164739
Purine nucleoside phosphorylase Bos taurus (cattle)Ki0.0000AID1571175; AID164739
Purine nucleoside phosphorylasePlasmodium falciparum (malaria parasite P. falciparum)Ki0.0102AID1578781; AID1578782; AID536622

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, uridine phosphorylase, putativePlasmodium falciparum 3D7Kd0.0009AID977611
Chain B, uridine phosphorylase, putativePlasmodium falciparum 3D7Kd0.0009AID977611
Chain A, Uridine phosphorylase putativePlasmodium falciparum 3D7Kd0.0009AID977611
Chain B, Uridine phosphorylase putativePlasmodium falciparum 3D7Kd0.0009AID977611
Chain A, Purine nucleoside phosphorylaseHomo sapiens (human)Kd0.0009AID977611
Purine nucleoside phosphorylaseHomo sapiens (human)Kd0.0001AID536621
Purine nucleoside phosphorylase Bos taurus (cattle)Kd0.0000AID694066

Other Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Purine nucleoside phosphorylase Bos taurus (cattle)Kieq0.0000AID694063

Bioassays (56)

Assay IDTitleYearJournalArticle
AID1578787Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes assessed as reduction in [3H]ethanolamine incorporation incubated for 18 hrs followed by addition of [3H]ethanolamine and measured after 48 hrs by scintillation countin2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
ISSN: 1520-4804		Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID409913Initial binding affinity to wild type human PNP2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
ISSN: 1464-3405		Immucillins in custom catalytic-site cavities.
AID272825Inhibition of DNA synthesis in CCRF-CEM cells assessed as inhibition of [3H]Thymidine incorporation upto 100 nM2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
ISSN: 0022-2623		Simplified analogues of immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity.
AID536621Inhibition of human PNP2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
ISSN: 1768-3254		Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase.
AID409921Ratio of relative binding Km/Ki for wild type human PNP to relative binding affinity Km/Ki for human PNP His257Gly mutant2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
ISSN: 1464-3405		Immucillins in custom catalytic-site cavities.
AID272833Antiproliferative activity against CCRF-CEM cells2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
ISSN: 0022-2623		Simplified analogues of immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity.
AID462377Inhibition of calf spleen PNP assessed as inhibition of 7-methylguanosine phosphorolysis after 50 mins by spectrophotometry in presence of 50 mM inorganic phosphate2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
ISSN: 1464-3391		Structural-based design and synthesis of novel 9-deazaguanine derivatives having a phosphate mimic as multi-substrate analogue inhibitors for mammalian PNPs.
AID409920Ratio of Km for human PNP His257Gly mutant to Ki for human PNP His257Gly mutant relative to inosine2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
ISSN: 1464-3405		Immucillins in custom catalytic-site cavities.
AID523342Antiparasitic activity against chloroquine-sensitive Plasmodium falciparum Ghana assessed as reduction in parasite growth after 3 days by fluorimetry2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID523341Antileishmanial activity against Leishmania infantum MHOM/MA/67/ITMAP263 intracellular amastigotes assessed as reduction in parasite growth after 3 days by fluorometrically2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID523340Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 s-galactosidase strain assessed as reduction in parasite growth after 3 days by fluorometrically2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID164739Inhibitory activity of compound against bovine purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
ISSN: 0022-2623		8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID164742Dissociation constant against Human Purine Nucleoside Phosphorylase was reported2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
ISSN: 0022-2623		Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase.
AID1571176Inhibition of human PNP using inosine as substrate by xanthine oxidase coupled assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
ISSN: 2040-2511		The transition to magic bullets - transition state analogue drug design.
AID164938Inhibitory activity of compound against human purine nucleoside phosphorylase (PNP)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
ISSN: 0022-2623		Targeting the polyamine pathway with transition-state analogue inhibitors of 5'-methylthioadenosine phosphorylase.
AID1571177Inhibition of bovine spleen PNP assessed as dissociation half life using inosine as substrate by xanthine oxidase coupled assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
ISSN: 2040-2511		The transition to magic bullets - transition state analogue drug design.
AID409914Equilibrium binding affinity to wild type human PNP2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
ISSN: 1464-3405		Immucillins in custom catalytic-site cavities.
AID409916Ratio of Km for wild type human PNP to Ki for wild type human PNP relative to inosine2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
ISSN: 1464-3405		Immucillins in custom catalytic-site cavities.
AID272824Inhibition of human dCK activity2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
ISSN: 0022-2623		Simplified analogues of immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity.
AID523326Inhibition of Trypanosoma brucei brucei Inosine guanosine nucleoside hydrolase2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID523324Inhibition of Trypanosoma vivax Inosine-adenosine-guanosine-nucleoside hydrolase2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID694066Binding affinity to calf recombinant PNP expressed in Escherichia coli BL21 (DE3) by isothermal titration calorimetry2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
ISSN: 1464-3391		Trimeric purine nucleoside phosphorylase: exploring postulated one-third-of-the-sites binding in the transition state.
AID1578784Inhibition of human PNP assessed as inhibitor constant for enzyme-inhibitor-substrate complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
ISSN: 1520-4804		Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID1578782Inhibition of Plasmodium falciparum His-tagged PNP assessed as inhibitor constant for enzyme-inhibitor-substrate complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
ISSN: 1520-4804		Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID523328Antitrypanosomal activity against suramin sensitive Trypanosoma brucei brucei Lister 427 assessed as reduction in parasite growth after 3 days by fluorometrically2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID410191Initial binding affinity to human PNP His257Gly mutant2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
ISSN: 1464-3405		Immucillins in custom catalytic-site cavities.
AID1578783Inhibition of human PNP assessed as inhibitor constant for enzyme-inhibitor complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
ISSN: 1520-4804		Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID1571178Oral bioavailability in mouse2018MedChemComm, Dec-01, Volume: 9, Issue:12
ISSN: 2040-2511		The transition to magic bullets - transition state analogue drug design.
AID164744Inhibitory activity of compound against human purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
ISSN: 0022-2623		8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID272823Inhibition of human PNP activity2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
ISSN: 0022-2623		Simplified analogues of immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity.
AID92759Inhibitory activity of compound against inosine-uridine nucleoside hydrolase (IU-NH) from crithidia fasciculata2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
ISSN: 0022-2623		8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID92758Inhibitory activity of compound against perine-specific inosine-adenosine-guanosine nucleoside hydrolase (IAG-NH) from Trypanosoma brucei2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
ISSN: 0022-2623		8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID164604Rate constant of compound was determined for interaction with bovine purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
ISSN: 0022-2623		8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID1571175Inhibition of bovine spleen PNP using inosine as substrate by xanthine oxidase coupled assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
ISSN: 2040-2511		The transition to magic bullets - transition state analogue drug design.
AID164930Equilibrium dissociation constant determined against human purine nucleoside phosphorylase (PNP) after slow-onset inhibition2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
ISSN: 0022-2623		Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
AID409918Equilibrium binding affinity to human PNP His257Gly mutant2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
ISSN: 1464-3405		Immucillins in custom catalytic-site cavities.
AID694063Inhibition of bovine PNP using 7-methylguanosine as substrate by spectrophotometric based coupled assay2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
ISSN: 1464-3391		Trimeric purine nucleoside phosphorylase: exploring postulated one-third-of-the-sites binding in the transition state.
AID523327Inhibition of human purine nucleoside phosphorylase2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID523329Cytotoxicity against human MRC5 SV2 cells after 48 hrs2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID523325Inhibition of Trypanosoma brucei brucei inosine-adenosine-guanosine nucleoside hydrolase (IAG-NH)2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
ISSN: 1098-6596		Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
AID1578781Inhibition of Plasmodium falciparum His-tagged PNP assessed as inhibitor constant for enzyme-inhibitor complex formation2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
ISSN: 1520-4804		Plasmodium Purine Metabolism and Its Inhibition by Nucleoside and Nucleotide Analogues.
AID164928Inhibition of human purine nucleoside phosphorylase; Initial rate.2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
ISSN: 0022-2623		Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
AID536622Inhibition of Plasmodium falciparum PNP expressed in Escherichia coli BL21(DE3) cells by spectrophotometry2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
ISSN: 1768-3254		Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase.
AID164740Rate constant of compound was determined for interaction with human purine nucleoside phosphorylase (PNP)2003Journal of medicinal chemistry, Jan-02, Volume: 46, Issue:1
ISSN: 0022-2623		8-Aza-immucillins as transition-state analogue inhibitors of purine nucleoside phosphorylase and nucleoside hydrolases.
AID164741Binding affinity towards Human Purine Nucleoside Phosphorylase was reported2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
ISSN: 0022-2623		Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase.
AID371442Inhibition of human PNP by xanthine-oxidase coupled assay2009Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4
ISSN: 1520-4804		Third-generation immucillins: syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase.
AID424677Inhibition of human purine nucleoside phosphorylase2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
ISSN: 1464-3405		Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.
AID1811Experimentally measured binding affinity data derived from PDB2006Journal of molecular biology, Jun-02, Volume: 359, Issue:2
ISSN: 0022-2836		Transition-state complex of the purine-specific nucleoside hydrolase of T. vivax: enzyme conformational changes and implications for catalysis.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Journal of molecular biology, Jun-02, Volume: 359, Issue:2
ISSN: 0022-2836		Transition-state complex of the purine-specific nucleoside hydrolase of T. vivax: enzyme conformational changes and implications for catalysis.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346173Human purine nucleoside phosphorylase (Nucleoside synthesis and metabolism)1998Biochemistry, Jun-16, Volume: 37, Issue:24
ISSN: 0006-2960		One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.
AID1811Experimentally measured binding affinity data derived from PDB2001Biochemistry, Jul-27, Volume: 40, Issue:28
ISSN: 0006-2960		Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with immucillin-H and its pieces.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Biochemistry, Jul-27, Volume: 40, Issue:28
ISSN: 0006-2960		Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with immucillin-H and its pieces.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2001Biochemistry, Jan-30, Volume: 40, Issue:4
ISSN: 0006-2960		Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis.
AID1811Experimentally measured binding affinity data derived from PDB2001Biochemistry, Jan-30, Volume: 40, Issue:4
ISSN: 0006-2960		Transition state structure of purine nucleoside phosphorylase and principles of atomic motion in enzymatic catalysis.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004The Journal of biological chemistry, Apr-30, Volume: 279, Issue:18
ISSN: 0021-9258		Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function.
AID1811Experimentally measured binding affinity data derived from PDB2004The Journal of biological chemistry, Apr-30, Volume: 279, Issue:18
ISSN: 0021-9258		Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function.

Research

Studies (108)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (2.78)18.2507
2000's65 (60.19)29.6817
2010's33 (30.56)24.3611
2020's7 (6.48)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (6.42%)5.53%
Reviews25 (22.94%)6.00%
Case Studies2 (1.83%)4.05%
Observational1 (0.92%)0.25%
Other74 (67.89%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
1,5-diazabicyclo(4.3.0)non-5-ene
0
pyrrolopyrimidine00low000000
antalarmin
0
pyrrolopyrimidine;
tertiary amino compound		corticotropin-releasing factor receptor antagonist00low000000
2-(1,3-dimethyl-2,4,6-trioxo-5,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)-N-(2-methoxyphenyl)acetamide
0
pyrrolopyrimidine00low000000
2-[[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]thio]-3-methyl-5H-pyrimido[5,4-b]indol-4-one
0
pyrimido-indole;
pyrrolopyrimidine		00low000000
b 43
0
aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector		00low000000
tofacitinib
0
N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound		antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		00low000000
batzelladine a
0
alkaloid;
carboxylic ester;
guanidines;
organic heterotricyclic compound;
pyrrolopyrimidine;
triazaacenaphthylene		anti-HIV-1 agent;
metabolite		00low000000
pevonedistat
0
cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer		00low000000
3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile
0
pyrrolopyrimidine00low000000
incb-018424
0
nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		00low000000
3-[(2-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone
0
pyrrolopyrimidine00low000000
baricitinib
0
azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide		anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent		00low000000
3-[(4-fluorophenyl)methyl]-5-methyl-4-thieno[3,4]pyrrolo[1,3-d]pyrimidinone
0
pyrrolopyrimidine00low000000
delgocitinib
0
azaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide		anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor		00low000000
pf 956980
0
N-acylpiperidine;
N-acylpyrrolidine;
pyrrolopyrimidine;
tertiary amino compound		EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor00low000000
gsk2656157
0
biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor		00low000000
queuine
0
pyrrolopyrimidineEscherichia coli metabolite00low000000
pemetrexed
0
N-acyl-L-glutamic acid;
pyrrolopyrimidine		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor		00low000000
7-deaza-2'-deoxyguanosine
0
pyrrolopyrimidine00low000000
immucillin g
0
dihydroxypyrrolidine;
pyrrolopyrimidine		00low000000
mirodenafil
0
aromatic ether;
N-alkylpiperazine;
primary alcohol;
pyrrolopyrimidine;
sulfonamide		EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent		00low000000
2,5-dihydroxymethyl-3,4-dihydroxypyrrolidine
0
dihydroxypyrrolidine00low000000
adenosine diphosphate (hydroxymethyl)pyrrolidinediol
0
dihydroxypyrrolidine;
purine ribonucleoside 5'-diphosphate		00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
chloroquine
1
aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug		2010201014.0low000100
tubercidin
1
antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite		201920195.0low000010
2-chloroadenosine
1
purine nucleoside201920195.0low000010
nsc 65346
1
nucleoside analogueprotein kinase inhibitor201920195.0low000010
coformycin
1
coformycinsEC 3.5.4.4 (adenosine deaminase) inhibitor201920195.0low000010
adefovir
1
6-aminopurines;
ether;
phosphonic acids		antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent		201920195.0low000010
adefovir dipivoxil
1
6-aminopurines;
carbonate ester;
ether;
organic phosphonate		antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug		201920195.0low000010
adenosine
1
adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent		201920195.0low000010
psicofuranine
1
psicose derivative;
purine nucleoside		201920195.0low000010
4-nitrobenzylthioinosine
1
purine nucleoside201920195.0low000010
9-(s)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine
1
201920195.0low000010
9-(3-hydroxy-2-phosphonomethoxypropyl)-2,6-diaminopurine
1
201920195.0medium000010
6-(4-nitrobenzylthio)guanosine
1
201920195.0low000010
5-iodotubercidin
1
organoiodine compound201920195.0low000010
angustmycin a
1
6-aminopurines201920195.0low000010
n(6)-methyl-2'-deoxyadenosine
1
purine 2'-deoxyribonucleoside201920195.0medium000010
pentostatin
1
coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor		201920195.0low000010
1,4-dideoxy-1,4-iminoarabinitol, (2r-(2alpha,3beta,4beta))-isomer
2
pyrrolidines2010201810.0high000110
galidesivir
1
201820186.0low000010
acyclovir
1
2-aminopurines;
oxopurine		antimetabolite;
antiviral drug		201820186.0low000010
guanine
1
2-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2012201212.0low000010
hypoxanthine
2
nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite201220198.5low000020
inosine
3
inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		200820199.0low000120
8-amino-9-(2-thienylmethyl)guanine
1
201820186.0medium000010
8-amino-9-benzylguanine
1
201820186.0medium000010
peldesine
1
201820186.0low000010
acyclovir monophosphate
1
201820186.0high000010
immucillin g
6
dihydroxypyrrolidine;
pyrrolopyrimidine		2003201914.8high000420
ulodesine
5
2003201912.6high000320
9-deazaguanine
1
2012201212.0low000010
9-deazahypoxanthine
1
2001200123.0medium000100
9-deaza-9-(3-thienylmethyl)guanine
1
201820186.0low000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
adenine
5
6-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2004202111.4low000221
arsenic acid
1
arsenic oxoacidEscherichia coli metabolite2004200420.0low000100
glycine
1
alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical		2008200816.0low000100
hydrogen
1
elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite		2005200519.0low000100
melatonin
1
acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger		2003200321.0low000100
purine
1
purine2005200519.0low000100
pyruvic acid
1
2-oxo monocarboxylic acidcofactor;
fundamental metabolite		2004200420.0low000100
mercaptoethanol
1
alkanethiol;
primary alcohol		geroprotector2009200915.0low000100
mechlorethamine
1
nitrogen mustard;
organochlorine compound		alkylating agent2007200717.0low000100
vorinostat
2
dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor		2007201214.5low100110
thalidomide
3
phthalimides;
piperidones		2010201213.3low100210
prednisone
1
11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug		2008200816.0low000100
aspartic acid
1
aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter		2005200519.0low000100
tubercidin
1
antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite		2010201014.0low000100
asparagine
1
amino acid zwitterion;
asparagine;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		2002200222.0low000100
histidine
1
amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite		2008200816.0low000100
tryptophan
1
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite		2009200915.0low000100
xylitol
1
2004200420.0low000100
phosphoribosyl pyrophosphate
1
5-O-phosphono-D-ribofuranosyl diphosphateEscherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite		1999199925.0low001000
pyrroles
43
pyrrole;
secondary amine		1998201520.4medium1043720
piperidine
1
azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine		base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent		202120213.0low000001
pyrazines
2
diazine;
pyrazines		Daphnia magna metabolite2010201213.0low100110
methylthioinosine
1
purine ribonucleoside;
thiopurine		2004200420.0low000100
deoxycytidine
1
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2008200816.0low000100
d-alpha tocopherol
1
alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite		202020204.0low000010
stavudine
1
dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor		2003200321.0low000100
dithiothreitol
3
1,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent		2003200918.7low000300
vidarabine
2
beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic		2009201014.5low100200
deuterium
2
dihydrogen2001200521.0low000200
glutamic acid
1
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		2002200222.0low000100
gemcitabine
1
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic		2008200816.0low000100
lamivudine
1
monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug		2003200321.0low000100
adenosine
5
adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent		200820218.2low000131
neplanocin a
1
202020204.0low000010
bendamustine hydrochloride
3
2008201214.3low100210
clofarabine
4
adenosines;
organofluorine compound		antimetabolite;
antineoplastic agent		2007201613.5low000220
magnesium pyrophosphate
1
1999199925.0low001000
10-propargyl-10-deazaaminopterin
1
N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound		antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor		2010201014.0low000100
aminopterin
1
dicarboxylic acidEC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen		2010201014.0low000100
enzastaurin
2
indoles;
maleimides		2008201214.0low100110
lenalidomide
3
aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator		2010201213.3low100210
bortezomib
2
amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor		2010201213.0low100110
5'-methylthioadenosine
1
thioadenosinealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2005200519.0low000100
n-acetylneuraminic acid
1
N-acetylneuraminic acidsantioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite		2010201014.0low000100
hexacyanoferrate iii
1
2004200420.0low000100
sodium arsenite
1
arsenic molecular entity;
inorganic sodium salt		antibacterial agent;
antifungal agent;
antineoplastic agent;
carcinogenic agent;
herbicide;
insecticide;
rodenticide		2009200915.0low000100
acetyl coenzyme a
1
acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite		2009200915.0low000100
pyrophosphate
1
diphosphate ion1999199925.0low001000
fludarabine
2
purine nucleoside2009201014.5low100200
unithiol
1
2009200915.0low000100
succimer
1
dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid		chelator2009200915.0low000100
nadp
1
2004200420.0low000100
nelarabine
7
beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor;
prodrug		2006201414.7low000430
sirolimus
2
antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		2008201214.0low100110
antimony
1
metalloid atom;
pnictogen		2003200321.0low000100
arsenic
1
metalloid atom;
pnictogen		micronutrient2003200321.0low000100
involucrin
1
2003200321.0low000100
everolimus
1
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol		anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor		2012201212.0low100010
galidesivir
4
200820219.2low000121
piperidines
2
2003202112.0low000101
cyclosporine
1
2002200222.0low000100
acyclovir
1
2-aminopurines;
oxopurine		antimetabolite;
antiviral drug		2005200519.0low000100
deoxyguanosine
5
purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2003200818.4low000500
deoxyguanosine triphosphate
8
deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		2001202015.8low200530
guanosine monophosphate
2
guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite		1999200323.0low001100
guanosine triphosphate
1
guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor		2001200123.0low000100
guanine
2
2-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2003200520.0low000200
guanosine
2
guanosines;
purines D-ribonucleoside		fundamental metabolite2003200520.0low000200
hypoxanthine
5
nucleobase analogue;
oxopurine;
purine nucleobase		fundamental metabolite1999201220.2low001310
inosinic acid
1
inosine phosphate;
purine ribonucleoside 5'-monophosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite		1999199925.0low001000
inosine
9
inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		2001200919.4low000900
azaguanine
1
nucleobase analogue;
triazolopyrimidines		antimetabolite;
antineoplastic agent;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor		2005200519.0low000100
peldesine
1
2003200321.0low000100
immucillin g
10
dihydroxypyrrolidine;
pyrrolopyrimidine		1998201519.5high002620
ulodesine
3
2006201016.0medium000300
9-arabinofuranosylguanine
1
beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
DNA synthesis inhibitor		2011201113.0low000010
5'-deoxy-5'-methylthioinosine
1
5'-deoxyribonucleoside;
inosines		2004200420.0medium000100
pyrimidinones
96
1998202216.3high70470193
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Acute Disease0
1
2013201311.0low100010
Acute Lymphoid Leukemia0
2
2007201612.5low000110
Acute Myelogenous Leukemia0
1
2011201113.0low000010
Adverse Drug Event0
1
201520159.0low000010
African Sleeping Sickness0
1
2010201014.0low000100
Anaplastic Large-Cell Lymphoma0
1
2012201212.0low100010
ATLL0
3
2003201017.7low000300
B-Cell Chronic Lymphocytic Leukemia0
6
2006202013.7low100510
B-Cell Leukemia0
1
2007200717.0low000100
B-Cell Lymphoma0
2
2012201411.0low100020
B-Cell Prolymphocytic Leukemia0
1
2011201113.0low000010
Benign Neoplasms0
2
2006201016.0low000200
Black Fever0
2
201520159.0low000020
Brill-Symmers Disease0
1
2008200816.0low000100
Cancer of Skin0
5
2007201712.6low200230
Congenital Zika Syndrome0
1
202020204.0low000010
Cutaneous T-Cell Lymphoma0
2
2007201712.0low000110
Diffuse Large B-Cell Lymphoma0
1
2008200816.0low000100
Disease Models, Animal0
2
201520206.5low000020
Drug-Related Side Effects and Adverse Reactions0
1
201520159.0low000010
Erythroderma, Sezary0
3
2007201414.7low100210
Exanthem0
1
2012201212.0low100010
Exanthema0
1
2012201212.0low100010
Experimental Leukemia0
1
2006200618.0low000100
Germinoblastoma0
2
2006201215.0low100110
Graft vs Host Disease0
1
2002200222.0low000100
Graft-Versus-Host Disease0
1
2002200222.0low000100
Hematologic Malignancies0
2
2008201114.5low000110
Hematologic Neoplasms0
2
2008201114.5low000110
Infections, Plasmodium0
2
2004201912.5low000110
Leishmaniasis, American0
1
201520159.0low000010
Leishmaniasis, Cutaneous0
1
201520159.0low000010
Leishmaniasis, Visceral0
2
201520159.0low000020
Leucocythaemia0
1
2006200618.0low000100
Leukemia1
1
2006200618.0low000100
Leukemia-Lymphoma, Adult T-Cell0
3
2003201017.7low000300
Leukemia, Lymphoblastic, Acute, T Cell0
3
2007201413.3low000120
Leukemia, Lymphocytic0
1
2005200519.0low100100
Leukemia, Lymphocytic, Chronic, B-Cell1
6
2006202013.7low100510
Leukemia, Lymphocytic, T Cell0
3
2002200818.3low000300
Leukemia, Lymphoid0
1
2005200519.0low100100
Leukemia, Myeloid, Acute0
1
2011201113.0low000010
Leukemia, Pre-B-Cell0
1
2013201311.0low100010
Leukemia, Prolymphocytic, B-Cell0
1
2011201113.0low000010
Leukemia, T-Cell0
3
2002200818.3low000300
Local Neoplasm Recurrence0
1
2007200717.0low000100
Lymphocytopenia0
1
2012201212.0low100010
Lymphoma1
2
2006201215.0low100110
Lymphoma, B-Cell0
2
2012201411.0low100020
Lymphoma, Follicular0
1
2008200816.0low000100
Lymphoma, Large B-Cell, Diffuse0
1
2008200816.0low000100
Lymphoma, Large-Cell, Anaplastic0
1
2012201212.0low100010
Lymphoma, T Cell, Peripheral0
6
200820228.5low200222
Lymphoma, T-Cell0
2
2006201215.0low100110
Lymphoma, T-Cell, Cutaneous1
2
2007201712.0low000110
Lymphoma, T-Cell, Peripheral0
6
200820228.5low200222
Lymphopenia0
1
2012201212.0low100010
Malaria0
2
2004201912.5low000110
Malaria, Falciparum0
1
2011201113.0low000010
Malignant Melanoma0
1
2011201113.0low000010
Melanoma0
1
2011201113.0low000010
Mycosis Fungoides0
3
2007201413.0low200120
Neoplasms0
2
2006201016.0low000200
Parodontosis0
1
2013201311.0low000010
Periodontal Diseases0
1
2013201311.0low000010
Plasmodium falciparum Malaria0
1
2011201113.0low000010
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma0
1
2013201311.0low100010
Precursor Cell Lymphoblastic Leukemia-Lymphoma0
2
2007201612.5low000110
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma0
3
2007201413.3low000120
Recrudescence0
3
201220198.3low200030
Sensitivity and Specificity0
1
2011201113.0low000010
Sezary Syndrome0
3
2007201414.7low100210
Skin Neoplasms0
5
2007201712.6low200230
T-Cell Lymphoma0
2
2006201215.0low100110
Trypanosomiasis, African0
1
2010201014.0low000100
Zika Virus Infection0
1
202020204.0low000010

Pharmacokinetics (2)

ArticleYear
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Blood, , Aug-12, Volume: 116, Issue:6		2010
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Blood, , Dec-15, Volume: 106, Issue:13		2005

Bioavailability (4)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Clinical lymphoma, myeloma & leukemia, , Volume: 13, Issue:4		2013
Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
International immunopharmacology, , Volume: 3, Issue:4		2003
Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
International immunopharmacology, , Volume: 1, Issue:6		2001

Dosage (3)

ArticleYear
Forodesine in the treatment of cutaneous T-cell lymphoma.
Expert opinion on investigational drugs, , Volume: 26, Issue:6		2017
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Blood, , Aug-12, Volume: 116, Issue:6		2010
Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2'-deoxyguanosine in primates.
International immunopharmacology, , Volume: 3, Issue:4		2003